TABLE 2.

Estimated Coefficients of Key Covariates from a Multinomial Logistic Regression

Variable		NOAC	Effect	P Value	EXP (Effect)
Intercept		Dabigatran	−2.35	< 0.0001	0.10
		Rivaroxaban	−2.95	< 0.0001	0.05
Time vs. July 4, 2012–December 31, 2012	October 1, 2010–March 3, 2011	Dabigatran	−0.69	< 0.0001	0.50
	October 1, 2010–March 3, 2011	Rivaroxaban	−16.21	0.930	0.00
	March 4, 2011–July 3, 2011	Dabigatran	0.19	0.020	1.21
	March 4, 2011–July 3, 2011	Rivaroxaban	−16.14	0.930	0.00
	July 4, 2011–November 3, 2011	Dabigatran	0.48	< 0.0001	1.62
	July 4, 2011–November 3, 2011	Rivaroxaban	−5.61	< 0.0001	0.00
	November 4, 2011–March 3, 2012	Dabigatran	0.41	< 0.0001	1.51
	November 4, 2011–March 3, 2012	Rivaroxaban	−1.62	< 0.0001	0.20
	March 4, 2012–July 3, 2012	Dabigatran	0.31	< 0.0001	1.37
	March 4, 2012–July 3, 2012	Rivaroxaban	−0.44	< 0.0001	0.65
Region vs. Northeast	Midwest	Dabigatran	−0.28	< 0.0001	0.75
	Midwest	Rivaroxaban	0.11	0.490	1.11
	South	Dabigatran	0.19	0.000	1.21
	South	Rivaroxaban	0.83	< 0.0001	2.29
	West	Dabigatran	−0.02	0.830	0.98
	West	Rivaroxaban	0.07	0.700	1.07
Age vs. < 65 years	65–74	Dabigatran	0.62	< 0.0001	1.87
	65–74	Rivaroxaban	0.36	0.100	1.44
	75 or older	Dabigatran	0.53	< 0.0001	1.69
	75 or older	Rivaroxaban	0.54	0.010	1.72
Sex	Women	Dabigatran	−0.08	0.090	0.92
	Women	Rivaroxaban	0.24	0.010	1.28
Race vs. White	Black	Dabigatran	−0.38	0.000	0.68
	Black	Rivaroxaban	−0.54	0.010	0.58
	Hispanic	Dabigatran	−0.18	0.110	0.83
	Hispanic	Rivaroxaban	−0.15	0.570	0.86
	Asian	Dabigatran	0.10	0.550	1.10
	Asian	Rivaroxaban	0.10	0.790	1.10
	Other	Dabigatran	0.22	0.210	1.25
	Other	Rivaroxaban	−0.21	0.650	0.81
Death	Died	Dabigatran	−0.58	< 0.0001	0.56
	Died	Rivaroxaban	−0.68	0.010	0.51
Patient’s insurance, cost-sharing status, and drug coverage benefit at the initiation of an anticoagulant vs. non-LIS in the initial phase	Dual-eligibles	Dabigatran	−0.35	< 0.0001	0.71
	Dual-eligibles	Rivaroxaban	−0.62	< 0.0001	0.54
	Non-dual LIS	Dabigatran	−0.26	0.010	0.77
	Non-dual LIS	Rivaroxaban	−0.39	0.080	0.67
	Non-LIS in the coverage gap phase	Dabigatran	−0.03	0.790	0.97
	Non-LIS in the coverage gap phase	Rivaroxaban	−0.22	0.320	0.80
	Non-LIS in the catastrophic phase	Dabigatran	0.35	0.130	1.42
	Non-LIS in the catastrophic phase	Rivaroxaban	−0.49	0.420	0.62
	National PACE or employer-sponsored	Dabigatran	0.31	< 0.0001	1.36
	National PACE or employer-sponsored	Rivaroxaban	0.24	0.090	1.28
Preexisting chronic conditions	Acute myocardial infarction	Dabigatran	−0.27	0.010	0.77
	Acute myocardial infarction	Rivaroxaban	0.07	0.710	1.07
	Stroke/transient ischemic attack	Dabigatran	−0.19	0.000	0.83
	Stroke/transient ischemic attack	Rivaroxaban	−0.53	< 0.0001	0.59
	Chronic kidney disease	Dabigatran	−0.40	< 0.0001	0.67
	Chronic kidney disease	Rivaroxaban	−0.34	0.000	0.71
	Congestive heart failure	Dabigatran	−0.29	< 0.0001	0.75
	Congestive heart failure	Rivaroxaban	−0.49	< 0.0001	0.61
	Hypertension	Dabigatran	0.40	< 0.0001	1.49
	Hypertension	Rivaroxaban	0.58	0.000	1.79
Previous use of other medications	NSAID	Dabigatran	0.48	< 0.0001	1.62
	NSAID	Rivaroxaban	0.72	< 0.0001	2.05
	Antiplatelet	Dabigatran	0.16	0.070	1.18
	Antiplatelet	Rivaroxaban	0.11	0.560	1.12

Note: Variables were selected by the stepwise variable selection method. Thirteen variables were selected among 37 variables.

LIS = low-income subsidy; NOAC = novel oral anticoagulant; NSAID = nonsteroidal anti-inflammatory drug; PACE = Programs of All-Inclusive Care for the Elderly.